Key result
Shugan Xiaozhi decoction significantly reduced serum ALT, AST, and lipid levels in a dose-dependent manner in rats with high-fat diet-induced nonalcoholic steatohepatitis.
Why the study?
Does Shugan Xiaozhi decoction improve nonalcoholic steatohepatitis in high-fat-fed rats?
RCT
randomly divided
Does Shugan Xiaozhi decoction improve nonalcoholic steatohepatitis in high-fat-fed rats?
Shugan Xiaozhi decoction protects liver function and relieves hepatic steatosis in a rat model of NASH by upregulating PPARα and L-FABP.
SX attenuates rat NASH; hypothesis-generating, human trials needed before any clinical consideration.
This study aimed to investigate the effects of Shugan Xiaozhi decoction (SX) on nonalcoholic steatohepatitis (NASH) induced by high‐fat diet in rats. The rats were randomly divided into 6 groups, namely, control, model, fenofibrate, and three different dosage of SX (10, 20, and 40 g/kg/day, p.o.). After establishing the NASH model, at 8 weeks of the experiment, treatments were administrated intragastrically to the fenofibrate and SX groups. All rats were killed after 4 weeks of treatment. Compared with the model group, alanine aminotransferase (ALT), aspartate aminotransferase (AST), free fatty acid (FFA), total cholesterol (TC), triacylglycerol (TG), and low‐density lipoprotein cholesterol (LDL) serum in the serum were significantly reduced in all SX treatment groups in a dose‐dependent manner. Evidence showed that SX could protect the liver by upregulating the gene and protein expressions of peroxisome proliferator‐activated receptor alpha (PPARα) and liver fatty acid binding protein (L‐FABP) in a dose‐dependent manner. Chemical constituents of SX were further analyzed by ultraperformance liquid chromatography coupled with electrospray ionization mass spectrometry (UPLC‐ESI‐MS) and 30 chemicals in the ethanolic extract were tentatively identified. To conclude, our results clearly indicated that SX could protect liver functions and relieve hepatic steatosis and inflammation.
No takes yet. Share an insight, caveat, or question.
Xing et al. (2016) conducted an RCT in Nonalcoholic steatohepatitis (NASH). Shugan Xiaozhi decoction (SX) vs. Control, model, and fenofibrate was evaluated on Serum levels of ALT, AST, FFA, TC, TG, and LDL. Shugan Xiaozhi decoction significantly reduced serum ALT, AST, and lipid levels in a dose-dependent manner in rats with high-fat diet-induced nonalcoholic steatohepatitis.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: